Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04763408 · ClinicalTrials.gov registry record
A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma
A clinical trial, sponsored by Eisai.
- Completed
- Registry status
- 335
- Enrollment target
NCT04763408: Completed study, sponsored by Eisai.
NCT04763408 is a clinical trial that has completed, run by Eisai. The registered enrollment target is 335 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04763408 has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- 335 participants
- Enrollment target
Study Summary
The primary purpose of this study is to further characterise the hepatotoxicity in participants with advanced or unresectable hepatocellular carcinoma (HCC) treated with lenvatinib, and to further characterise the overall safety profile (serious adverse events \[SAEs\], grade 3 to 5 adverse events \[AEs\], dose modifications and discontinuations due to AEs) in participants with advanced or unresectable HCC treated with lenvatinib.
Interventions
- DRUG Lenvatinib
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2021-04-09 |
| Est. Completion | 2023-12-13 |
What the finished NCT04763408 record still lists
NCT04763408 is an observational study that tracks outcomes without assigning an intervention. The registered 335 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Lenvatinib is the first listed.
NCT04763408 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04763408 about?
NCT04763408 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma". The primary purpose of this study is to further characterise the hepatotoxicity in participants with advanced or unresectable hepatocellular carcinoma (HCC) treated with lenvatinib, and to further characterise the overall safety profile (serious adverse events \[SAEs\], grade 3 to 5 adverse events \...
What is the current status of trial NCT04763408?
This trial is currently completed. The enrollment target is 335 participants. The study started on 2021-04-09. Estimated completion is 2023-12-13.
What interventions are being tested in trial NCT04763408?
The interventions under investigation include: Lenvatinib (DRUG), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT04763408?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04134754 · 335 participants · NA
Carbon Dioxide (CO2) Chemosensitivity and SUDEP
- NCT05554406 · 335 participants · Phase 2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- NCT06183437 · 335 participants · Phase 4
The STOP-MED CTRCD Trial
- NCT06885177 · 335 participants · NA
TECTONIC CAD IVL IDE Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI